<DOC>
	<DOCNO>NCT02839304</DOCNO>
	<brief_summary>The objective study demonstrate safety feasibility PolarStar system subject Paroxysmal Atrial Fibrillation .</brief_summary>
	<brief_title>Investigation Adagio PolarStar System Patients With Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>1 . Patient diagnose paroxysmal atrial fibrillation ablation procedure deem appropriate therapy . 2 . Reported incidence least two ( 2 ) document episode symptomatic paroxysmal atrial fibrillation ( PAF ) six month precede trial entry ( least one episode document rhythm strip ECG ) . 3 . Failure least one antiarrhythmic medication ( AAD ) paroxysmal atrial fibrillation [ class I III , AV nodal block agent beta blocker ( BB ) calcium channel blocker ( CCB ) ] evidence recurrent symptomatic paroxysmal atrial fibrillation , intolerable side effect due AAD . 4 . Left atrial size &lt; 50 mm large dimension measure image document preoperative imaging ( CT , MRI and/or TTE ) 5 . Left Ventricular Ejection Fraction ≥ 40 % ( obtain within 12 month prior procedure ) . 6 . Anticoagulation therapy : patient receive anticoagulation therapy appropriate accord 2014 AHA/ACC/HRS Guideline Management Patients Atrial Fibrillation . 7 . Patient least 18 ≤80 year age . 8 . Patient able willing give inform consent . 1 . Patient previous leave atrial ablation . 2 . History valvular cardiac surgical procedure , atrial septal defect closure device ; leave atrial appendage closure device . 3 . Coronary artery bypass grafting ( CABG ) procedure within last 3 month . 4 . Awaiting cardiac transplantation cardiac surgery within next 12 month . 5 . Atrial clot/thrombus image transesophageal echocardiogram ( TEE ) perform within 48 hour procedure deem appropriate investigator . 6 . History document thromboembolic event within past one ( 1 ) year . 7 . Diagnosed atrial myxoma . 8 . Patient defibrillator implant . 9 . Patient known cryoglobulinemia . 10 . Patient contraindication oral anticoagulation . 11 . Anaphylactic allergy contrast medium . 12 . Significant pulmonary disease , ( e.g . restrictive pulmonary disease , constrictive chronic obstructive pulmonary disease ) disease malfunction lungs respiratory system produce chronic symptom . 13 . Significant congenital anomaly medical problem opinion investigator would preclude enrollment study . 14 . Acute illness active systemic infection sepsis . 15 . Unstable angina . 16 . Myocardial infarction within previous three month . 17 . History blood clot bleed abnormality . 18 . Uncontrolled heart failure New York Heart Association ( NYHA ) class III IV heart failure . 19 . An intracardiac thrombus , tumor , abnormality precludes catheter introduction manipulation . 20 . Presence condition precludes vascular access 21 . Patient renal dysfunction glomerular filtration rate &lt; 30 ml/min/1.73m2 . 22 . Structural heart disease clinical significance include congenital heart disease either underlying abnormality correction prohibit increase risk ablation . 23 . Atrial fibrillation ( AF ) secondary electrolyte imbalance , thyroid disease , reversible noncardiac cause ( e.g . surgery , pericarditis ) . 24 . Any history cerebrovascular disease , include stroke Transient Ischemic Attack . 25 . Previous continuous AF episode last &gt; 7 day . 26 . Continued need Amiodarone therapy post procedure . 27 . Women pregnant ( history menstrual period pregnancy test history consider unreliable ) . 28 . Any anatomical abnormality patient 's esophagus might interfere esophageal warm balloon insertion , position inflation . 29 . Enrollment investigational study evaluate another device drug . 30 . Life expectancy le 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>